Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Black Diamond Therapeutics (BDTX) Non-Current Assets (2018 - 2025)

Black Diamond Therapeutics (BDTX) has disclosed Non-Current Assets for 3 consecutive years, with $32.6 million as the latest value for Q3 2021.

  • For the quarter ending Q3 2021, Non-Current Assets rose 225.57% year-over-year to $32.6 million, compared with a TTM value of $75.5 million through Sep 2021, down 51.11%, and an annual FY2020 reading of $10.1 million, up 291.94% over the prior year.
  • Non-Current Assets was $32.6 million for Q3 2021 at Black Diamond Therapeutics, up from $16.9 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $141.2 million in Q2 2020 and bottomed at $717000.0 in Q1 2020.
  • Average Non-Current Assets over 3 years is $28.8 million, with a median of $13.0 million recorded in 2020.
  • Peak annual rise in Non-Current Assets hit 2119.25% in 2021, while the deepest fall reached 88.01% in 2021.
  • Year by year, Non-Current Assets stood at $2.6 million in 2019, then soared by 291.94% to $10.1 million in 2020, then skyrocketed by 222.06% to $32.6 million in 2021.
  • Business Quant data shows Non-Current Assets for BDTX at $32.6 million in Q3 2021, $16.9 million in Q2 2021, and $15.9 million in Q1 2021.